Literature DB >> 14575152

Pathomechanisms of paraneoplastic myasthenia gravis.

Philipp Ströbel1, Tobias Preisshofen, Markus Helmreich, Hans Konrad Müller-Hermelink, Alexander Marx.   

Abstract

Thymic T cell development is characterized by sequential selection processes to ensure generation of a self-tolerant, immuncompetent mature T cell repertoire. Malfunction of any of these selection processes may potentially result in either immunodeficiency or autoimmunity. Myasthenia gravis (MG) is a typical autoimmune manifestation of thymic epithelial tumors (thymomas) and is related to the capacity of these tumors to generate and export mature T cells. Analysis of the factors that lead to autoimmunization in thymomas will help to understand the mechanisms that prevent MG under physiological conditions in humans. In a comparison of MG(+) and MG(-) thymomas, we could show that only thymomas capable of generating mature CD45RA+CD4+ T cells are associated with MG (p < 0.0001), while terminal thymopoiesis was abrogated in MG(-) thymomas. In particular, acquisition of the CD27+CD45RA+ phenotype appears to be a critical checkpoint of late T cell development in the human thymus and may play an important role in the prevention of autoimmunity. Moreover, MG(-) thymomas were virtually depleted of regulatory (CD4+CD25+) T cells (regT), while regT were readily detectable in MG(+) thymomas, albeit at significantly reduced numbers compared to control thymuses. Thus, in MG(+) thymoma patients, thymectomy apparently also results in removal of a regulatory T cell pool and may explain the frequent temporary postoperative deterioration of MG in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575152      PMCID: PMC2270674          DOI: 10.1080/10446670310001598528

Source DB:  PubMed          Journal:  Clin Dev Immunol        ISSN: 1740-2522


  8 in total

1.  Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Francesca Ciaraffa; Giovanni Scambia; Amelia Evoli
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

2.  Paraneoplastic diseases associated with thymoma.

Authors:  Amelia Evoli; Giacomo Maria Minicuci; Roberta Vitaliani; Alessandra Battaglia; Giacomo Della Marca; Libero Lauriola; Andrea Fattorossi
Journal:  J Neurol       Date:  2007-02-26       Impact factor: 4.849

3.  Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Giacomo Minicuci; Raffaella Riso; Laura Peri; Giovanni Scambia; Amelia Evoli
Journal:  J Clin Immunol       Date:  2007-11-14       Impact factor: 8.317

4.  Metaplastic thymoma with myasthenia gravis presumably caused by an accumulation of intratumoral immature T cells: a case report.

Authors:  Shogo Tajima; Masahiro Yanagiya; Masaaki Sato; Jun Nakajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 5.  Thymus and autoimmunity.

Authors:  Alexander Marx; Yosuke Yamada; Katja Simon-Keller; Berthold Schalke; Nick Willcox; Philipp Ströbel; Cleo-Aron Weis
Journal:  Semin Immunopathol       Date:  2021-02-03       Impact factor: 9.623

Review 6.  Therapeutic Plasma Exchange: For Cancer Patients.

Authors:  Yuru Hu; Hanshan Yang; Shaozhi Fu; Jingbo Wu
Journal:  Cancer Manag Res       Date:  2022-02-02       Impact factor: 3.989

7.  cFLIP overexpression in T cells in thymoma-associated myasthenia gravis.

Authors:  Djeda Belharazem; Berthold Schalke; Ralf Gold; Wilfred Nix; Mario Vitacolonna; Peter Hohenberger; Eric Roessner; Torsten J Schulze; Güher Saruhan-Direskeneli; Vuslat Yilmaz; German Ott; Philipp Ströbel; Alexander Marx
Journal:  Ann Clin Transl Neurol       Date:  2015-07-22       Impact factor: 4.511

8.  Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes.

Authors:  Yosuke Yamada; Cleo-Aron Weis; Julian Thelen; Carsten Sticht; Berthold Schalke; Philipp Ströbel; Alexander Marx
Journal:  Front Immunol       Date:  2020-04-16       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.